Adventrx sees positive results using CoFactor against colorectal cancer

New York, Oct. 21 - Adventrx Pharmaceuticals, Inc. said it has presented positive preclinical data from a study using CoFactor against colorectal cancer at the American Association for Cancer Research special conference, Colorectal Cancer: Molecular Pathways and Therapies.

The study suggests that CoFactor in combination with 5-fluorouracil and oxaliplatin may be an effective chemotherapeutic regimen against colorectal cancer, with higher efficacy and lower toxicity than the equivalent 5-fluorouracil, oxaliplatin and leucovorin regimen, the San Diego-based company said.

"While combination therapy with 5-FU, leucovorin and oxaliplatin has shown improved clinical efficacy in treating colorectal cancer compared with 5-FU and leucovorin, optimum efficacy with oxaliplatin combination therapy might not be achieved in this combination due to multiple factors," said Mark Cantwell, Adventrx's director of preclinincal programs, in a news release.

"Among these are oxaliplatin's well characterized toxicity and that leucovorin may contribute to the severity of 5-FU's systemic toxicity.

"Preclinical data suggest that CoFactor as a replacement for leucovorin may result in improved overall efficacy and lower toxicity of 5-FU-containing regimens. CoFactor has already demonstrated antitumor activity with an apparent safer toxicity profile in combination with 5-FU in Phase I and Phase II clinical trials in treatment of metastatic colorectal cancer."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.